Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.

ABSTRACT:

Objectives

Epigenetic modifiers were important players in the development of haematological malignancies and sensitivity to therapy. Mutations of SET domain-containing 2 (SETD2), a methyltransferase that catalyses the trimethylation of histone 3 on lysine 36 (H3K36me3), were found in various myeloid malignancies. However, the detailed mechanisms through which SETD2 confers chronic myeloid leukaemia progression and resistance to therapy targeting on BCR-ABL remain unclear.

Materials and methods

The level of SETD2 in imatinib-sensitive and imatinib-resistant chronic myeloid leukaemia (CML) cells was examined by immunoblotting and quantitative real-time PCR. We analysed CD34⁺ CD38^- leukaemic stem cells by flow cytometry and colony formation assays upon SET

SUBMITTER: Sheng Y 

PROVIDER: S-EPMC6668982 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature